YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 04, 16:00
5067.30
-117.05 (-2.26%)
VOLUME 37,926
LIVE
NSE
May 04, 15:59
5067.25
-118.7 (-2.29%)
VOLUME 795,618
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's Laboratories shares rise 2% on launch of Albendazole tablets in US

12.46 pm | 30 Apr 2021 |  Source: Moneycontrol.com

The share touched a 52-week high of Rs 5,514.65 and a 52-week low of Rs 3,613.45 on 21 September 2020 and 18 May 2020, respectively....

Dr Reddy's expects first lot of Russia's COVID-19 vaccine Sputnik V by May end

11.54 am | 27 Apr 2021 |  Source: PTI

In September 2020, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of SputnikV, developed by the Gamaleya National Research I...

Dr Reddy's Lab share price gains 4% on plans to launch Sputnik V by early June

12.52 pm | 20 Apr 2021 |  Source: Moneycontrol.com

The share touched a 52-week high of Rs 5,514.65 and a 52-week low of Rs 3,588.25 on 21 September, 2020 and 09 April, 2020, respectively....

Dr Reddy's says it will be importing Sputnik V vaccine from Russia during first quarter of FY22

6.34 pm | 14 Apr 2021 |  Source: Moneycontrol.com

Dr Reddy's as per its licensing agreement with can produce up to 250 million doses of the Sputnik V vaccine, the deal allows to expand the volumes...

Dr Reddy's working on stability data on 2 to 8 degrees temperature range for Sputnik V vaccine

5.35 pm | 14 Apr 2021 |  Source: PTI

The doses will be kept outside for 15-20 minutes before being administered to the people....

Accumulate Dr Reddy's Laboratories; target of Rs 5400: Dolat Capital Market

1.46 pm | 13 Apr 2021 |  Source: Moneycontrol.com

Dolat Capital Market recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5400 in its research report dated April 1...

Telangana records 3,052 new COVID-19 cases, 7 deaths

10.43 am | 13 Apr 2021 |  Source: PTI

The total number of cases stood at 3,32,581 while with 778 patients being cured, the total recoveries were at 3,06,678. The state has 24,131 active ca...

India gets 3rd COVID-19 vaccine, DCGI approves Sputnik V for emergency use

8.47 am | 13 Apr 2021 |  Source: Moneycontrol.com

Kirill Dmitriev told CNBC-TV18 that they are working out pricing with the government. RDIF has hinted that the Sputnik V will be sold at less than ...

Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

8.42 pm | 12 Apr 2021 |  Source: Moneycontrol.com

Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan....

COVID-19 vaccine | India may become a manufacturing hub for Russia's Sputnik: Report

10.07 am | 01 Apr 2021 |  Source: Moneycontrol.com

Russian Direct Investment Fund has reportedly signed agreements with companies such as Gland Pharma, Virchow Biotech, Strides Pharma Science and Heter...

'Dr Reddy's expects Sputnik V vaccine to get approval from Indian regulator in next few weeks'

1.19 pm | 29 Mar 2021 |  Source: PTI

It is a two-dose vaccine. You take the first dose on day zero and the second one on day 21. The peak immunity develops somewhere between day 28 to day...

Buy Dr Reddy’s Laboratories: target of Rs 6500: Sharekhan

1.34 pm | 05 Mar 2021 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated ...

Buy Dr Reddy's Laboratories; target of Rs 5200: Dolat Capital Market

11.48 pm | 09 Feb 2021 |  Source: Moneycontrol.com

Dolat Capital Market is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5200 in its research ...

Buy Dr Reddy’s Laboratories; target of Rs 6500: Sharekhan

10.52 pm | 09 Feb 2021 |  Source: Moneycontrol.com

Sharekhan is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 6500 in its research report dated ...

Cadila: COVID vaccine to be the key differentiator in the near term

9.23 am | 09 Feb 2021 |  Source: Moneycontrol.com

In the next fiscal, Cadila plans to launch 40-plus products, including 8-10 complex molecules which should offset pricing erosion...

Buy Dr. Reddy's Laboratories; target of Rs 5406: Prabhudas Lilladher

3.44 pm | 08 Feb 2021 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5406 in its research ...

Weekly Tactical Pick | Dr Reddy's Laboratories

9.23 am | 05 Feb 2021 |  Source: Moneycontrol.com

Vaccine scope, strong product pipeline to act as tonic for Dr Reddy's Laboratories...

Buy Dr Reddy’s Laboratories; target of Rs 5525: ICICI Direct

5.22 pm | 04 Feb 2021 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5525 in its research report dat...

Neutral Dr Reddy’s Labs; target of Rs 5070: Motilal Oswal

9.09 pm | 02 Feb 2021 |  Source: Moneycontrol.com

Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 5070 in its research report dated January 30, 2021....

Dr Reddys Labs Standalone December 2020 Net Sales at Rs 3,408.20 crore, up 11.96% Y-o-Y

9.22 am | 02 Feb 2021 |  Source: Moneycontrol.com

NULL...

1 2
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.